Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells

Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, John Scholler, Simon F. Lacey, Jan J. Melenhorst, Farzana Nazimuddin, Jessica Perazzelli, David A. Christian, Christopher A. Hunter, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill

Research output: Contribution to journalArticle

2 Scopus citations
Original languageEnglish (US)
Article numberO5
JournalJournal for ImmunoTherapy of Cancer
Volume3
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Scholler, J., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., Perazzelli, J., Christian, D. A., Hunter, C. A., Porter, D. L., June, C. H., Grupp, S. A., & Gill, S. (2015). Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. Journal for ImmunoTherapy of Cancer, 3, [O5]. https://doi.org/10.1186/2051-1426-3-S2-O5